Investors

Investors 2018-02-05T09:29:16+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

Powerful Trial Design to Lead Next Stage DMX-200 Chronic Kidney Disease Subgroup Studies

Highlights  • Dimerix to launch next stage of lead program, DMX-200, with two simultaneous Phase 2 clinical trials in the area of Chronic Kidney Disease • Leading global contract research organisation IQVIA has been engaged; [...]

ASX: Lead investigator engaged for DMX-200 Phase 2 trials

Dimerix is pleased to announce that Professor Simon Roger, Director of Renal Research in Gosford, New South Wales, will serve as Principal Investigator for the Company’s coming DMX-200 Phase 2 clinical efficacy trials. Professor David Power, [...]

ASX: Completion of Unmarketable Parcel Sale Facility

The directors of Dimerix are pleased to advise completion of the unmarketable parcel sale facility, first announced on 9 March 2018. The full announcement is available here.

ASX: Dimerix to Further Bolster Management Team

Dimerix is pleased to announce management team changes designed to support the company in the next phase of its lead program for the treatment of Chronic Kidney Disease, DMX-200 and developing its Receptor HIT platform [...]

Read More

Media Coverage

Analyst coverage: Bioshares update 18 May 2018

Bioshares have published a summary of the recent activities and program developments at Dimerix. The report is available here.

Powerful Trial Design to Lead Next Stage DMX-200 Chronic Kidney Disease Subgroup Studies

Highlights  • Dimerix to launch next stage of lead program, DMX-200, with two simultaneous Phase 2 clinical trials in the area of Chronic Kidney Disease • Leading global contract research organisation IQVIA has been engaged; [...]

ASX: Lead investigator engaged for DMX-200 Phase 2 trials

Dimerix is pleased to announce that Professor Simon Roger, Director of Renal Research in Gosford, New South Wales, will serve as Principal Investigator for the Company’s coming DMX-200 Phase 2 clinical efficacy trials. Professor David Power, [...]

ASX: Completion of Unmarketable Parcel Sale Facility

The directors of Dimerix are pleased to advise completion of the unmarketable parcel sale facility, first announced on 9 March 2018. The full announcement is available here.

Read More

Analyst Reports

Analyst coverage: Bioshares update 18 May 2018

Bioshares have published a summary of the recent activities and program developments at Dimerix. The report is available here.

Analyst coverage: Updated NDF Research note

NDF Research have updated their coverage note titled "Dimerix - DMX-200's credibility increases" The report is available here.

Baker Young DXB Flash Note November 2017

Read this here. 

Bioshares November 2017

View their report here. 

Read More

Stock Quote

View stock price: ASX Stock Price

Corporate Fact Sheet

Most recent fact sheet: February 2018

Email Alert

subscribe to news updates